Tickets are sold out. Sign up for the waiting list if you are still interested in attending.
Join MAPS in creating a post-prohibition world, where psychedelics can be used for therapy, to inspire creativity, to promote environmental stewardship, to help solve global conflicts, and to accomplish personal or spiritual growth.
Reserve your seats today to network among the company of like-minded individuals, enjoy dinner and wine, and show your support for psychedelic research by donating to MAPS' mission. Meet movers and shakers in the psychedelic research community, including MAPS staff, scientists, and celebrities who support our work.
Breakthrough Therapy Designation
Preliminary studies have shown that MDMA combined with psychotherapy can help people overcome PTSD. After careful review of these studies, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to MDMA for the treatment of PTSD. By granting Breakthrough Therapy Designation, the FDA has agreed that this treatment may have a meaningful advantage and greater compliance over available medications for PTSD. Breakthrough Therapy Designation also means that the FDA will work closely with MAPS to complete Phase 3 trials, the final phase of research, as efficiently as possible.
Phase 3 trials require more clinical sites, more therapists, more patients, and more support. This research is crucial to receiving government approval of MDMA-assisted psychotherapy as a legal treatment, which would radically shift policy and public perception surrounding psychedelics.
Together, we can work to heal millions of people suffering from PTSD by supporting groundbreaking research into psychedelic therapies. This research is essential to obtaining government approval of MDMA-assisted psychotherapy as a legal treatment, which would radically shift policy and public perception surrounding psychedelics. There is a need unmet by modern psychiatry and psychotherapy that psychedelic-assisted therapies can fill.
We can create this future together. Join us in opening the doors to new models for healing and personal growth. Proceeds from the event benefit MAPS’ research and education programs.
MAPS Founder and Executive Director, Rick Doblin, Ph.D., will host an illuminating conversation about how the path to legalizing psychedelic medicine leads to his vision of a post-prohibition world; where psychedelics are used as prescription medicines, as valuable tools for inspiring creativity, for personal and spiritual growth, and for catalyzing resolutions to global and social conflicts. His professional goal is to become a legally licensed psychedelic therapist.
Aubrey Marcus, Founder and CEO, ONNIT, created ONNIT as a lifestyle brand based on a holistic health philosophy he calls Total Human Optimization. Since its founding, Onnit has become an Inc. 500 company and industry leader with over 250 products ranging from peak performance supplements to foods, fitness equipment, and apparel. Aubrey currently hosts The Aubrey Marcus Podcast, a destination for conversations with the brightest minds in athletics, business, science, and philosophy with over 10MM downloads on iTunes. A sought-after public speaker and multi-platform media expert, Aubrey regularly provides commentary to outlets like Entrepreneur, Forbes, Fusion, The Doctors, Dr. Oz, and The Joe Rogan Experience.
Alli Feduccia, Ph.D., Clinical Data Scientist, received a bachelor’s degree in Biological Psychology in 2009 from Louisiana State University. After earning a Ph.D. in Neuropharmacology from the University of Texas at Austin by utilizing rodent models to study the effects of MDMA on behavior and neurochemical release, she held a postdoctoral research position in the Preclinical Development Group at Ernest Gallo Clinic and Research Center at the University of California San Francisco where her experiments aimed to discover novel treatment strategies for alcohol dependence by elucidating the mechanisms of action of medications used to treat substance use disorders. At MAPS PBC, Alli is currently serving as the Clinical Data Scientist, performing various tasks to ensure clinical data is analyzed and communicated in the highest quality for regulatory documents, scientific publications, and public presentations. She also makes online e-learning modules and creates content for a web-based learning management system to host training and educational material for site and therapy teams, Zendo Project, and other public educational outreach. Alli is passionate about starting a MAPS-sponsored trial of ayahuasca for treatment of alcohol use disorders and is currently applying her translational perspective to the development of a new protocol.
We are grateful for the art generously donated by Nanu Berks and Jarett Leger, with music by Michael Garfield.
Artist Jarrett Leger
Artist Nanu Berks
Sunday, February 4, 2018
Time: Doors opened at 7:00 PM
Barton Creek Neighborhood
Special thanks to our hosts, Aubrey Marcus and Whitney Miller, and to our host committee (in formation): Jade Netanya Ullmann, Robert Barnhart, Roland Wiederaenders, Jason Havey, Josh Bezoni, and Max Kerr.
Questions? Contact firstname.lastname@example.org
The Multidisciplinary Association for Psychedelic Studies (MAPS) is a non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. Founded in 1986, MAPS’ highest priority is to develop MDMA-assisted psychotherapy into an FDA-approved prescription treatment for PTSD.